ILE DE FRANCE

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Retrieved on: 
Mardi, mars 5, 2024
CNRS, Regeneration, Crohn's disease, EIC, Exosome, Quality of life, Fistula, Stenosis, B cell, Patient, Fibrosis, Intellectual property, Congress, Research, ECCO, Pharmaceutical industry

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Key Points: 
  • Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
  • This new worldwide license marks a significant step forward in EVerZom's mission to bring innovative exosome-based therapeutic solutions to patients suffering from serious digestive diseases.
  • Paris, March 5, 2024 - EVerZom, a CNRS/Université Paris Cité spin-off specializing in exosomes, has announced the signature of a second exclusive license agreement with Erganeo for the development of EVerGel ™, a drug candidate tailored for the healing of digestive tissues.
  • EVerZom's first clinical application focuses on digestive tissue regeneration using naive exosomes derived from stem cells encapsulated in a gel called EVerGel ™.

EVerZom: Therapeutic Ambition in Exosome Biotherapies

Retrieved on: 
Mercredi, décembre 13, 2023
Urine, RNA, Liver, Quality of life, Dicarboxylic acid, Protein, Partnership, NASH, IND, Big Pharma, Acute liver failure, Saliva, Crohn's disease, Regenerative medicine, Lung cancer, Diffusion, Blood, Doctor of Philosophy, Cirrhosis, Fistula, Accelerator, Exosome, Lipid, FedEx, CNRS, Engineering, EIC, Cell, Patient, Publication, Safety, Therapy, Pharmaceutical industry

Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.

Key Points: 
  • Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.
  • This revolutionary drug modality constitutes a new therapeutic era for acellular off the shelf therapeutics, opening up new opportunities in cell and gene therapy.
  • This platform addresses the entire technological value chain, from cell to patient: cell sourcing, exosome generation, engineering and formulation.
  • Leveraging its innovation platform, EVerZom’s ambition is to develop its pipeline of proprietary biotherapies in regenerative medicine, while building partnerships in several other indications.

PECULIUM Secures 10 Million Capital Commitment from Global Emerging Markets (GEM)

Retrieved on: 
Jeudi, mai 5, 2022
Decentralized finance, Investment, Ecosystem, PIPES, Lists of companies, PSAN, ICO, Financial technology, CIF, Marketing, OKX, PCL, Solution, AUM, Public–Private Investment Program for Legacy Assets, GEM, Growth, Acquisition, Private investment in public equity, Cryptocurrency

PECULIUM has developed a full range of AI-powered investment management tools on the blockchain focusing to bring savings management to everyone.

Key Points: 
  • PECULIUM has developed a full range of AI-powered investment management tools on the blockchain focusing to bring savings management to everyone.
  • PECULIUM is an official broker partner with a handful of the most reputable exchanges in the world, including Binance, Huobi and OKX.
  • Global Emerging Markets ("GEM") is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets and has completed over 480 transactions in 70 countries from 5 continents.
  • The launch of the PECULIUM Token (PCL) was another major step in this direction for PECULIUM.